Ontada is committed to reflecting the most current activity in the community oncology setting through our products and solutions. Our unique relationship with the country’s leading community oncology network, The US Oncology Network, means we deliver near-real time data, insights and research that reflects how cancer is treated in the community, where an estimated 85% of cancer patients seek care.[1] Our embedded point-of-care solutions allow us to quickly adapt to new guidelines, biomarkers and treatments, and offer timely insights from the community.
Access real-world data derived from the leading community oncology network through our market-leading EHR, iKnowMed, and other point-of-care solutions like Clear Value Plus. Equipped with actionable insights from real-world data, life sciences companies can maximize commercial success, generate real-world evidence, enhance drug development and improve patient outcomes.
Our innovative, award-winning EHR, iKnowMed, was designed for and by community oncologists for the specific demands of oncology care. iKnowMed rapidly integrates new guidelines and biomarkers, ensuring real-time data capture that enhances decision-making and improves patient outcomes.
Ontada Learn addresses the evolving needs of oncology practitioners by working with life sciences companies to provide tailored educational content and updates on new treatments and testing guidelines, in a variety of formats that meet every learning style, preference and schedule.
Ontada’s research expertise spans the entire research process, from proposal to publication. Whether it’s clinical support from practicing oncologists who act as principal investigators or research support from Ontada’s Medical Office and researchers who have supported more than 350 real-world publications, Ontada’s comprehensive approach ensures clinical expertise throughout the research journey for robust and impactful studies.
Contact us today to learn how Ontada can support your real-world data needs, research initiatives or provider education goals.
Ontada’s extensive reach in oncology is anchored by our connections to The US Oncology Network, the leading community oncology network, and Onmark practices. These unique partnerships provide us with unparalleled insights into treatment and testing patterns across a vast network of community oncologists, enhancing our ability to deliver impactful oncology solutions.
Everything we do is to help our partners improve the lives of cancer patients
Speed to insights
Gain accelerated access to insights with Ontada’s ON.Genuity platform which leverages innovative AI to unlock accurate, actionable, and insight-rich data and evidence at scale
Early signals
Discover emerging trends from real-world data that rapidly reflects changes as clinical guidelines and oncology care standards evolve
Precise targeting
Leverage detailed clinical and biomarker to drive precision medicine
Unparalleled clinical depth
Ontada’s ON.Genuity platform combines the leading community oncology clinical dataset with advanced technology, capturing insights at point of care and delivering data with unmatched clinical depth
Keep up with Ontada
Microsoft
Ontada announces collaboration with Microsoft that transformed 150 million pieces of unstructured data four times faster by leveraging Azure Batch API. This initiative significantly enhances the ability to generate meaningful and actionable insights faster and at scale.
Read moreCancer Moonshoot
Ontada recently collaborated with the White House Cancer Moonshot program, contributing to the Enhancing Oncology Model (EOM) submission protocol. The White House shared our contributions in press release, highlighting the role we played in combatting cancer and our dedication to transforming cancer care.
Read moreU.S. Food & Drug Administration
In late 2023, the U.S. FDA called on Ontada to lead research into rare cancers treated in community oncology. This research will provide clinical context to inform future research opportunities, as well as a comprehensive understanding of how best to interpret these findings.
Read more